AstraZeneca - AZN Share Forecast, Price & News

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca Stock Performance

LON:AZN opened at £110.14 ($133.08) on Friday. The company has a debt-to-equity ratio of 87.31, a current ratio of 0.96 and a quick ratio of 0.67. The business has a 50 day moving average price of £107.03 and a 200 day moving average price of £101.17. The company has a market capitalization of £170.66 billion and a P/E ratio of -187.31. AstraZeneca has a 1-year low of GBX 8,029 ($97.02) and a 1-year high of £112.90 ($136.41).

AstraZeneca Cuts Dividend

The business also recently declared a dividend, which will be paid on Monday, September 12th. Shareholders of record on Thursday, August 11th will be given a dividend of GBX 76.40 ($0.92) per share. This represents a yield of 0.7%. The ex-dividend date of this dividend is Thursday, August 11th. AstraZeneca's payout ratio is -4.82%.

Analysts Set New Price Targets

AZN has been the topic of a number of recent research reports. Barclays boosted their price objective on AstraZeneca from £120 ($145.00) to £125 ($151.04) and gave the stock an "overweight" rating in a research note on Thursday, August 4th. UBS Group set a £101 ($122.04) price objective on AstraZeneca in a research note on Tuesday, June 14th. Shore Capital reissued a "buy" rating on shares of AstraZeneca in a research note on Monday, August 8th. The Goldman Sachs Group set a GBX 6,950 ($83.98) price objective on AstraZeneca in a research note on Friday, April 29th. Finally, set a £120 ($145.00) price objective on AstraZeneca in a research note on Monday, August 1st. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, AstraZeneca has a consensus rating of "Buy" and an average price target of £106.96 ($129.24).